1132 Background: Recent guidelines recommend minimizing breast cancer screening for women over the age of 75. This study examines the presentation and outcome of older patients with breast cancer to determine if increasing screening among older patients may result in better outcomes. Methods: A prospective database at Hackensack University Medical Center was queried for all patients with breast cancer diagnosed between 1/1/2006 and 1/1/2011. Numerical values compared by Student’s t -test; categorical values by Fisher exact test. Median time to events determined by Kaplan-Meier; outcomes compared by log-rank test. Results: 2200 patients were identified (> 75 years, n=335, < 75 years, n=1865). Among the older cohort, mean age was 81 +/- 4 years (range: 75 – 101); mean tumor size was 2.3 +/- 0.1 cm (range: .1 – 12). Most tumors were invasive and localized (in-situ: 12.7%, localized: 57.3%, node positive: 24.0%, metastatic: 5.8%) and most commonly ductal histology (ductal: 77.0%; lobular: 16.6%, mixed:6.2%). Only 10.0% of patients with invasive disease and 29.2% with positive nodes received systemic therapy; 90.2% underwent surgical resection. Disease-free and overall 5 year survival was 54.9% and 62.9% (in-situ: 82.2%; localized: 67.1%; node positive: 57%; metastatic 22%). Older patients had larger tumors (2.30 +/- .11 v. 1.91 +/- .04 cm; p<0.001), more locally advanced (T4) disease (6.7% v. 1.7%, p<.001), more invasive disease (89% v. 84%, p<.01). Older patients had less positive family history (21.7% v. 37.3%, p<.0001). There was no difference between the groups in race, presentation with stage IV disease, tumor grade, lymphovascular invasion, histologic subtype, triple negativity, or nodal positivity. Overall and disease free five year survival were significantly worse for older patients (OS: 90.2% v. 63.9%, p< .0001; DFS: 80.9% v. 54.9%, p<.0001). Conclusions: Breast cancer among older women leads to worse outcomes compared to younger patients, regardless of histology, invasiveness of disease, hormonal status, nodal status or tumor grade. Older women present with more invasive disease, larger tumors and more locally advanced disease, despite having less family history. This implies that continued screening beyond age 75 may lead to less advanced presentation and better outcomes.